These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 15224366

  • 21. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 25. Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
    Fang B, Song Y, Han Z, Wei X, Lin Q, Zhu X, Yang R, Sun J, Tian G, Liu X, Cao G, Shi Y, Nie N, Li D, Zhao RC.
    Leuk Res; 2007 Oct 15; 31(10):1441-4. PubMed ID: 17383001
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S, Falcone U, Celentano M, Coppola M, Ferrara MG, Sica A.
    Leuk Res; 2009 Aug 15; 33(8):1079-81. PubMed ID: 19167064
    [Abstract] [Full Text] [Related]

  • 28. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D.
    Med Hypotheses; 2008 Aug 15; 70(1):128-36. PubMed ID: 17566666
    [Abstract] [Full Text] [Related]

  • 29. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
    Srinivas U, Pillai LS, Kumar R, Pati HP, Saxena R.
    Am J Hematol; 2007 Apr 15; 82(4):314-6. PubMed ID: 17013815
    [Abstract] [Full Text] [Related]

  • 30. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
    Carella AM, Lerma E.
    Ann Hematol; 2007 Oct 15; 86(10):749-52. PubMed ID: 17576558
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S, Yano K, Kobayashi M.
    Gan To Kagaku Ryoho; 2003 Mar 15; 30(3):427-30. PubMed ID: 12669406
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P.
    J Assoc Physicians India; 2005 Apr 15; 53():291-5. PubMed ID: 15987013
    [Abstract] [Full Text] [Related]

  • 37. [Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia].
    Miyazaki K, Kon S, Watanabe T, Togano T, Ohsaka M, Suzuki Y, Danbara M, Horie R, Kanda Y, Maruta A, Higashihara M.
    Rinsho Ketsueki; 2007 Apr 15; 48(4):297-304. PubMed ID: 17515120
    [Abstract] [Full Text] [Related]

  • 38. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A, Takayama N, Hasegawa Y, Kojima H, Nagasawa T.
    Gan To Kagaku Ryoho; 2003 Nov 15; 30(12):1997-9. PubMed ID: 14650975
    [Abstract] [Full Text] [Related]

  • 39. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
    Oku E, Imamura R, Nagata S, Takata Y, Seki R, Otsubo K, Hashiguchi M, Osaki K, Yakushiji K, Yoshimoto K, Ogata H, Sata M, Okamura T.
    Acta Haematol; 2007 Nov 15; 117(4):191-6. PubMed ID: 17170522
    [Abstract] [Full Text] [Related]

  • 40. Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis.
    Campiotti L, Codari R, Appio L, Ultori C, Solbiati F, Maria Grandi A, Venco A.
    Leuk Res; 2007 Dec 15; 31(12):1768-70. PubMed ID: 17403537
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.